Why FMC Corporation Plunged 72% in 2025

FMC Corp. shares plunged ~71.5% in 2025 after repeated revenue misses and two major negative earnings-period developments: in Feb. management provided full-year revenue guidance of $4.15–4.35B versus a $4.40B analyst consensus, and in Oct. the company recorded a 49% headline revenue hit after putting its India business up for sale, with adjusted revenue down ~10% for the quarter. Management slashed the dividend 86% from $0.58 to $0.08 to preserve cash, cut free cash flow guidance to ($200M)–$0 and said it will use proceeds and savings to pay down more than $4.5B of debt; manufacturing consolidation continues through end-2026 and new patent-protected product ramps are not expected until 2028. Investors should weigh near-term cash-collection pressures in South America, pricing pressure from off-patent generics, and sizable restructuring costs against speculative upside if portfolio divestitures and improved crop pricing restore margins.

Analysis

Market structure: FMC’s problems transfer value to competitors with deeper defensive pipelines (e.g., Corteva CTVA) and generic producers that gain share via lower prices; distributors are at risk as FMC shifts to direct-sales in South America. Pricing power for patent-protected chemistries is impaired until 2028, so expect margin compression of several hundred bps and continued revenue declines near-term as farmers delay purchases amid weak crop prices and higher local rates.

Risk assessment: Tail risks include a liquidity/crisis event if FCF stays in the ($200M) to $0 range and debt remains >$4.5B — a ratings downgrade or distressed debt restructuring is plausible within 6–18 months. Immediate risks (days–weeks) center on the India sale price and Q1 2026 cash collections; medium term (through end-2026) watch restructuring costs and covenant tests; long term (2028+) depends on new patent ramps.

Trade implications: Tactical short of FMC equity sized 2–3% of portfolio with a protective 12–18 month put spread (limit cost) or buy CDS where available; pair trade by going long CTVA (2–3%) and short FMC to capture relative margin and pipeline divergence. Credit play: consider FMC bonds only if yield-to-worst >12% and sale proceeds reach >$500M (improves leverage); otherwise avoid unsecured debt.

Contrarian angles: The market may be over-discounting upside from an India sale — if disposal fetches >$800M and working-cap improves 90–120 days post-close, equity could rally >50% from troughs. Hidden risk: aggressive cost cuts could hollow R&D, delaying 2028 recovery; monitor AR days in Brazil and corn/soy prices (corn >$5.00/bu or soy >$12.50/bu) as real catalysts for demand recovery.

Key Decisions for Investors

• Establish a 2–3% short position in FMC equity (NYSE: FMC) sized to portfolio risk, hedge with a 12–18 month FMC put spread (buy 12-month OTM put, sell cheaper further OTM put) to cap premium; target profit if stock falls another 30–50% or cover if FCF turns >$0 for two consecutive quarters.
• Implement a relative-value pair: go long Corteva (CTVA) 2–3% and short FMC equal dollar; rebalance if CTVA/FMC spread narrows by 25% or when FMC reports sustainable cash collection improvement over two quarters.
• Do not buy FMC unsecured bonds unless yield-to-worst exceeds 12% and leverage (Net Debt/EBITDA) falls by ≥0.5x after India sale; if sale announced at >$800M, re-evaluate for selective credit exposure with 3–5 year maturities.
• Monitor three specific catalysts within 30–120 days: announced India sale proceeds (thresholds <$400M, $400–800M, >$800M), South America AR days trending down by ≥10 days, and quarterly FCF turning positive — use these to widen/narrow positions.